Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. by Egger, Matthias et al.
Correcting Mortality for Loss to Follow-Up: A Nomogram
Applied to Antiretroviral Treatment Programmes in Sub-
Saharan Africa
Matthias Egger
1*, Ben D. Spycher
1, John Sidle
2, Ralf Weigel
3, Elvin H. Geng
4, Matthew P. Fox
5, Patrick
MacPhail
6, Gilles van Cutsem
7, Euge `ne Messou
8, Robin Wood
9, Denis Nash
10, Margaret Pascoe
11, Diana
Dickinson
12, Jean-Franc ¸ois Etard
13, James A. McIntyre
14, Martin W. G. Brinkhof
1, for IeDEA East Africa,
West Africa and Southern Africa
1Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland, 2Moi University School of Medicine, Eldoret, Kenya, 3Lighthouse Trust, Kamuzu
Central Hospital, Lilongwe, Malawi, 4Division of HIV/AIDS, Department of Medicine, University of California, San Francisco, San Francisco, California, United States of
America, 5Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America, 6Right to Care, Themba Lethu Clinic, Helen
Joseph Hospital, Johannesburg, South Africa, 7Khayelitsha Me ´decins sans Frontie `res programme, University of Cape Town, Cape Town, South Africa, 8Centre de Prise en
Charge, de Recherche et de Formation sur le VIH/SIDA, Abidjan, Co ˆte d’Ivoire, 9Desmond Tutu HIV Centre, Cape Town, South Africa, 10Mailman School of Public Health,
Columbia University, New York, New York, United States of America, 11Newlands Clinic, Harare, Zimbabwe, 12Independent Surgery, Gaborone, Botswana, 13Institut de
Recherche pour le De ´veloppement/UMR 145, Montpellier, France, 14Perinatal HIV Research Unit, Soweto, South Africa
Abstract
Background: The World Health Organization estimates that in sub-Saharan Africa about 4 million HIV-infected patients had
started antiretroviral therapy (ART) by the end of 2008. Loss of patients to follow-up and care is an important problem for
treatment programmes in this region. As mortality is high in these patients compared to patients remaining in care, ART
programmes with high rates of loss to follow-up may substantially underestimate mortality of all patients starting ART.
Methods and Findings: We developed a nomogram to correct mortality estimates for loss to follow-up, based on the fact
that mortality of all patients starting ART in a treatment programme is a weighted average of mortality among patients lost
to follow-up and patients remaining in care. The nomogram gives a correction factor based on the percentage of patients
lost to follow-up at a given point in time, and the estimated ratio of mortality between patients lost and not lost to follow-
up. The mortality observed among patients retained in care is then multiplied by the correction factor to obtain an estimate
of programme-level mortality that takes all deaths into account. A web calculator directly calculates the corrected,
programme-level mortality with 95% confidence intervals (CIs). We applied the method to 11 ART programmes in sub-
Saharan Africa. Patients retained in care had a mortality at 1 year of 1.4% to 12.0%; loss to follow-up ranged from 2.8% to
28.7%; and the correction factor from 1.2 to 8.0. The absolute difference between uncorrected and corrected mortality at 1
year ranged from 1.6% to 9.8%, and was above 5% in four programmes. The largest difference in mortality was in a
programme with 28.7% of patients lost to follow-up at 1 year.
Conclusions: The amount of bias in mortality estimates can be large in ART programmes with substantial loss to follow-up.
Programmes should routinely report mortality among patients retained in care and the proportion of patients lost. A simple
nomogram can then be used to estimate mortality among all patients who started ART, for a range of plausible mortality
rates among patients lost to follow-up.
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The World Health Organization (WHO) estimates that about 4
million people were receiving antiretroviral therapy (ART) in low-
and middle-income countries by the end of 2008, with coverage
reaching 42% of the estimated 9.5 million in need of ART [1].
Sub-Saharan Africa represented 70% of the estimated treatment
need and 73% of the total number of people receiving treatment in
low- and middle-income countries at the end of 2008 [1].
The provision of ART in resource-limited settings follows a
public health approach, which is characterized by a limited
number of regimens and the standardization of clinical and
laboratory monitoring [2]. This approach has been shown to result
in similar or superior adherence to therapy and similar virological
response when compared to industrialized countries [3–5]. Loss of
patients to follow-up and care is, however, an important problem
in resource-limited settings: A systematic review of published
retention rates in ART clinics in sub-Saharan Africa showed that
the proportion of patients retained 2 years after starting therapy
was approximately 60% [6]. Similarly, in a collaborative analysis
of patients starting ART in 15 treatment programmes in Africa,
Asia, and South America we found that 21% of patients were lost
to follow-up 6 months after starting ART [7]. A systematic review
and meta-analysis of studies tracing patients lost to follow-up
found that these patients experience high mortality [8] compared
to patients remaining in care [9].
The successful treatment of individual patients and the
monitoring and evaluation of ART programmes both depend on
regular and complete patient follow-up. Programmes with high
rates of loss to follow-up and poor ascertainment of deaths in
patients lost will underestimate mortality of all patients starting
ART. For example, standard Kaplan-Meier survival analyses in
which follow-up time in patients lost to follow-up is censored at the
last visit will be biased because mortality of these patients is
assumed to be identical to comparable patients remaining in care.
Analyses restricted to patients remaining in care will also
underestimate mortality among all patients who started ART.
Biased estimates of programme-level mortality hamper the
evaluation of single programmes and the comparison between
different programmes and settings.
Nomograms are widely used in medicine [10]. They are graphs
that allow the approximate graphical computation of a function;
placing a line across its several scales immediately solves the
formula [11]. We propose a nomogram and a web-based
calculator to correct estimates of programme-level mortality for
loss to follow-up. We illustrate its use in a case study from Kenya.
We show how mortality among patients lost to follow-up can be
predicted on the basis of studies that traced patients to ascertain
their vital status. Finally, we apply these methods to 11 ART
programmes in sub-Saharan Africa and compare uncorrected and
corrected estimates of mortality at 1 year to assess the typical bias
that is introduced when loss to follow-up is ignored.
Methods
Deriving the Nomogram
Mortality of all patients starting ART in a treatment
programme over a defined time period is a weighted average of
mortality among patients remaining in care and patients lost to
follow-up. It depends on the percentage of patients lost, mortality
among patients lost to follow-up, and mortality among patients not
lost to follow-up. The mortality observed among patients
remaining in care can be multiplied by a correction factor C to
obtain an estimate of programme-level mortality that takes deaths
among patients lost to follow-up into account. This correction
factor can be obtained from a nomogram. The algebraic
derivation of this nomogram is as follows:
Let
MU= Uncorrected estimates of programme-level mor-
tality (with censoring of patients lost)
MC= Corrected estimate of programme-level mortality,
taking deaths among patients lost into account.
MNL= Mortality observed in patients retained in care
(not lost to follow-up)
ML= Mortality estimated in patients lost to follow-up
r= Proportion lost to follow-up
Note that
MNL, ML, and r need to refer to the same time period (for
example the first year of ART).
Then
MC ~ 1{r ðÞ MNLz rM L:
Dividing both sides of this equation by MNL, we obtain the
correction factor
C ~ MC=MNL ~ 1{r ðÞ z rM L=MNL ðÞ
which can be used to obtain MC for a given MNL from MC=
MNLC.
The nomogram (Figure 1) plots the ratio of the mortality among
patients lost and not lost to follow-up (ML/MNL) on lines defined by
the proportion of patients lost to follow-up (r) which are used to
read off correction factor C. The broken lines refer to the case-
study described in Box 1. Further details on calculations are
provided in Text S1. Figures S1 and S2 provide clean versions of
the nomogram. These are also available from http://www.iedea-
sa.org.
Two Ways of Estimating Mortality among Patients Lost to
Follow-Up
The parameters r and MNL can be observed directly, but
mortality among patients lost to follow-up must be estimated. This
can be done in dedicated studies tracing patients lost to follow-up,
for example by visiting the homes of patients lost to follow-up or
by linking treatment programme with death registry data to
ascertain the vital status of patients lost to follow-up [12–15]. This
method will be henceforth be called ‘‘tracing method.’’
In many situations, however, data from dedicated tracing
studies are not available. In this case, mortality among patients lost
to follow-up may be predicted on the basis of published data from
similar settings. We used Brinkhof and colleagues’ systematic
review and meta-regression analysis of studies tracing patients lost
to follow-up [8]. The meta-regression analysis was based on a total
of 15 studies in patients on ART from sub-Saharan Africa. There
was an inverse relation between mortality among those lost to
follow-up and the rate of loss to follow-up in the programme: The
higher the rate of loss to follow-up the lower the mortality among
those lost. Figure 2 shows the predicted mortality among patients
lost to follow-up according to the percentage of patients lost in the
programme, with 95% confidence intervals (CIs). The equation is
as follows:
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where a=0.57287 and b=24.04409.
Mortality among patients lost to follow-up can be calculated
using the formula above or read off Figure 2, based on the
proportion of patients lost to follow-up in the programme. This
method will henceforth be called ‘‘meta method.’’
Allowing for Uncertainty
We used Monte Carlo simulations with 100,000 iterations to
calculate 95% CIs for the corrected programme-level mortality
(MC). These simulations allow for uncertainty in the estimation of
(i) mortality among patients remaining in care (MNL); (ii) in the
proportion of patients lost to follow-up (r); and (iii) of mortality
among patients lost to follow-up (ML). Further details are provided
in Text S1.
Application to ART Programmes in Sub-Saharan Africa
The International epidemiological Databases to Evaluate AIDS
(IeDEA, see http://www.iedea-hiv.org) is a collaborative network
of HIV/AIDS treatment programmes in seven regions of the
world, including North America, Asia and the Pacific, the
Caribbean and Latin America, and four regions in sub-Saharan
Africa (Central Africa, East Africa, West Africa, and Southern
Africa). IeDEA and its predecessor, the ART in Lower Income
Countries (ART-LINC) collaboration, have been described in
detail elsewhere [16–20]. These collaborative networks were
established to address clinical and operational research questions
that require large patient numbers or many treatment pro-
grammes, for example to compare outcomes of ART between
different settings, delivery modes, and types of monitoring.
We included 11 ART programmes from sub-Saharan Africa.
No direct evidence on the mortality of patients lost to follow-up
from tracing studies was available for these programmes, and
mortality was therefore predicted using the meta method. All
patients aged 16 years or older with complete data on sex and date
of birth, and who were treatment naı ¨ve at start of combination
ART were included in the analysis. Combination ART was
defined as a minimum of three antiretroviral drugs from two drug
classes. Advanced stage of disease was defined as WHO stages III
or IV or Centers for Disease Control and Prevention (CDC)
clinical stage C. Measurements of laboratory values closest to the
starting date of ART (within 6 months before up to one week after
the date of starting ART) were taken as the baseline levels. The
Figure 1. Nomogram for obtaining correction factors to adjust programme-level mortality estimates, based on the observed
mortality among patients not lost to follow-up, the observed proportion of patients lost and an estimate of mortality among
patients lost. The red dot and broken lines relate to the case study described in Box 1.
doi:10.1371/journal.pmed.1000390.g001
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analysed centrally. At all sites, institutional review boards had
approved the collection and transfer of data.
For each programme we determined the proportion of patients
lost to follow-up at 1 year (r). A patient was considered lost to
follow-up if the last visit was more than 9 months before the
closure date for that site, with the closure date defined as the most
recent visit date recorded in the database. This allowed for time
during which a patient could have returned for a visit. Only
patients who potentially had 9 months of follow-up were included
in the calculations of r. We used Kaplan-Meier methods to
estimate mortality (with 95% CI) at 1 year for patients remaining
in care (MNL).
Web Calculator
The calculations of the nomogram, the prediction of mortality
among patients lost to follow-up based on the meta-regression
analysis described above, and the calculation of 95% CIs have
been implemented on a dedicated website at http://www.iedea-sa.
org.
Results
Case Study from Western Kenya Using the Tracing
Method
Box 1 and Figure 1 illustrate the correction of naı ¨ve estimates
of programme-level mortality in six simple steps. The data are
from the Academic Model Providing Access to Healthcare
(AMPATH), a large ART programme in western Kenya [21,22].
Patients who miss scheduled appointments are actively traced by
outreach teams, and data from the outreach programme were
used to estimate mortality among patients lost to follow-up. The
data are based on a previous detailed analysis of two AMPATH
sites [23]. The uncorrected estimate (MU) of mortality at these
two sites for the period between 1 January 2005 and 31 January
2007 was 1.7% (95% CI 1.3%–2.0%) ,t h ee s t i m a t ef o rm o r t a l i t y
among patients not lost to follow-up was 2.2% (95% CI 1.8%–
16.6%), and the corrected estimate using the nomogram was
9.5% (Box 1). Entering the data into the web calculator at http://
www.iedea-sa.org/ gives a more precise corrected estimate of
programme mortality of 9.4%, with 95% CI 8.1%–10.9%. Of
note, the results from the nomogram are similar to the corrected
estimates that were obtained for these AMPATH sites by
Y i a n n o u t s o se ta l .u s i n gm o r ec omplex statistical methods
[23,24].
Correction of Mortality in ART Programmes in Sub-
Saharan Africa Using the Meta Method
A total of 24,257 patients from 11 ART programmes in 10
countries (Botswana, Co ˆte d’Ivoire, Kenya, Malawi, Rwanda,
Senegal, South Africa, Uganda, Zambia, Zimbabwe) were
included: 1,363 deaths were observed during the first year of
ART. Table 1 shows the characteristics of the 11 programmes.
Four programmes were located in South Africa and one
programme had sites in six different countries. The number of
patients treated at each site ranged from 369 to 4,705 patients.
Eight sites were public (government) clinics offering ART free of
charge, two were run by a nongovernmental organisation offering
free ART, one was a research site offering free ART, and one site
was a private clinic operating on a fee-for-service basis. Median
Box 1. Example from Western Kenya Using Tracing Method
The Academic Model Providing Access to Healthcare
(AMPATH) is a large ART programme in western Kenya
[21,22]. AMPATH is based on a partnership between the Moi
University School of Medicine in Eldoret and Indiana
University School of Medicine in Indianapolis, Indiana, United
States of America. AMPATH provides HIV care and treatment
to over 70,000 adults and children living with HIV/AIDS in 18
clinics throughout western Kenya. Patients are managed
according to National Kenyan protocols, which are consistent
with WHO guidelines. AMPATH undertakes active outreach
to patients who miss scheduled appointments (called lost to
follow-up in this article). A locator card is completed for all
patients enrolling in the programme, which includes contact
information and a map to the patient’s residence. The results
of the outreach programme have been described for the Moi
Teaching and Referral Hospital in the city of Eldoret and the
rural health centre in Mosoriot [23]. A total of 8,977 adult
patients were enrolled in the two participating sites; 3,624
patients were lost to follow-up and 5,353 remained in care
between 1 January 2005 and 31 January 2007. Outreach
efforts were initiated for 1,143 (31.5%) of patients lost and
the vital status of 621 (54.3%) patients could be determined.
The naı ¨vely calculated Kaplan-Meier (KM) estimate of
programme-level mortality (MU), ignoring loss to follow-up,
was 1.7%. This estimate can now be corrected in six simple
steps:
1. Determine the percentage of patients lost to follow-up (r):
3,624 of 8,977 patients were lost to follow-up: 40.5%
2. Determine mortality among patients lost to follow-up (ML):
124 of the 621 patients traced had died. The KM estimate was
20.0%
3. Determine mortality among patients not lost to follow-up
(MNL):
126 of the 5,353 patients remaining in care had died. The KM
estimate was 2.2%.
4. Calculate the ratio of mortality among patients lost to
follow-up and patients not lost to follow-up (ML divided by
MNL):
20.0 divided by 2.2 is 9.1
5. Obtain the correction factor C from the nomogram:
4.3 (see broken lines in Figure 1)
6. Calculate the corrected programme-level mortality:
4.3 times 2.2% is 9.5%
Not all patients lost to follow-up could be located and
mortality among those who could not be found might have
been even higher than in those who were successfully
traced. Overall mortality among patients lost to follow-up
may thus have been higher than 20%. The effect of assuming
a higher mortality among patients lost to follow-up can be
examined in a sensitivity analysis: repeating the steps
assuming that 25% or 30% of patients lost to follow-up
had died results in estimates of corrected programme-level
mortality of 11.4% and 13.5%. Clearly, deaths in patients lost
to follow-up are an important issue when estimating
programme-level mortality in the AMPATH programme.
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years) and 16,018 patients (66.0%) were women. The median
CD4 cell count at baseline ranged from 83 to 156 cells/mL across
programmes.
Table 2 lists the uncorrected estimates (MU) of programme-level
mortality at 1 year (which do not consider mortality among patients
lost to follow-up), the proportion of patients lost to follow-up at 1
year (r), the estimated 1-year mortality among patients remaining in
care (MNL), the predicted mortality among patients lost to follow-up
(ML, obtained from the meta-regression model of Brinkhof et al.
[8]), correction factor C and the corrected estimates of programme-
level mortality at 1 year (MC), which take mortality among patients
lost to follow-up into account, with 95% CIs calculated as described
above. Figure 3 shows the nomogram populated with the data from
the 12 antiretroviral treatment programmes.
The uncorrected estimates of programme-level mortality at 1
year ranged from 1.3% to 11.0%, mortality at 1 year among
patients retained in care from 1.4% to 12.0%; loss to follow-up at
1 year from 2.8% to 28.7%; and correction factor C from 1.19 to
8.04. The corrected estimates of programme-level mortality
ranged from 4.4% to 18.8%. Figure 4 shows a scatter plot of the
uncorrected estimates of programme-level mortality (MU) against
the corrected estimates (MC): the absolute difference between
uncorrected and corrected mortality at 1 year was relatively small
(1.7%–3.6%) in seven programmes, but more substantial in the
remaining four programmes. The largest difference in mortality
was 9.8%, in a programme with 28.7% of patients lost to follow-up
at 1 year. The uncorrected estimate of programme-level mortality
for this programme was 1.4% and the corrected estimate 11.2%.
Discussion
Regular and complete patient follow-up is essential both for
the care of individual patients and the monitoring and evaluation
of outcomes of ART programmes. Individual treatment
decisions can then be made in the light of clinical and laboratory
results and the rate of complications and mortality can be
accurately estimated at the programme level. Loss to follow-up
is, however, an important problem in ART programmes in
resource-limited settings [6,7,18,25], and poor ascertainment of
Figure 2. Predicted mortality among patients lost to follow-up according to percent of patients lost in programme (solid line) with
95% CI (limits of grey area). See text for regression equation.
doi:10.1371/journal.pmed.1000390.g002
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level mortality, i.e. mortality of all patients starting ART, is
underestimated [8,23]. Previous analyses of treatment pro-
grammes have generally censored follow-up time at the last visit
to the clinic, and patients lost to follow-up therefore contributed
follow-up time but no deaths [26–28] (here referred to as MU).
Table 1. Characteristics of ART programmes included in the study.
Site Location Characteristics
Patients,
n
Enrolment
Period,
Calendar Years
Women,
n (%)
Median
(IQR) Age,
Years
Median (IQR)
Baseline CD4
Cell Count,
Cells/mL
Advanced
clinical
stage, %
(95% CI)
a
ANRS 1215 Dakar, Senegal Research site, free
treatment
369 1998–2002 201 (54%) 38 (31–44) 121 (48–217) 55% (50–60)
CEPREF Abidjan, Co ˆte d’Ivoire Public, free treatment 2,643 1998–2007 1,941 (73%) 35 (30–42) 132 (52–217) 81% (80–83)
Independent
Surgery
Gaborone, Botswana Private clinic,
fee-for-service
662 1996–2007 393 (59%) 36 (32–41) 118 (53–187) Not assessed
ISS clinic Mbarara, Uganda Public, free treatment 3,713 1996–2007 2,173 (59%) 36 (31–42) 99 (35–181) 81% (79–82)
Lighthouse Lilongwe, Malawi Public, free treatment
since June 2004
4,705 2004–2007 2,811 (60%) 36 (30–42) 126 (54–211) 86% (85–87)
Newlands Harare, Zimbabwe NGO, free treatment 857 1996–2007 585 (68%) 37 (32–44) 102 (51–159) 68% (63–72)
Gugulethu Cape Town, South Africa Public, free treatment 1,896 2002–2006 1,294 (68%) 33 (29–39) 103 (50–160) 80% (78–82)
Khayelitsha Cape Town, South Africa Public, free treatment 3,366 2001–2005 2,353 (70%) 32 (28–38) 87 (35–146) 90% (89–91)
PHRU Soweto, South Africa Public, free treatment 528 2001–2005 373 (71%) 35 (30–41) 83 (33–139) 45% (40–49)
Themba
Lethu
Johannesburg, South
Africa
Public, free treatment 3,694 1996–2006 2,491(67%) 35 (30–41) 87 (34–152) 97% (96–97)
MTCT-Plus
Initiative
Sites in South Africa,
Zambia, Kenya, Rwanda,
Uganda, Co ˆte d’Ivoire
NGO, family based care,
free treatment
1,824 1996–2006 1,403 (77%) 30 (27–35) 156 (93–198) 40% (38–42)
aDefined as WHO stages III or IV or Centers for Disease Control and Prevention (CDC) clinical stage C.
ANRS, Agence Nationale de Recherches sur le SIDA et les He ´patites Virals; CEPREF, Centre de Prise en Charge de Recherche et de Formation; IQR, interquartile range; ISS
Immune Suppression Syndrome clinic; MTCT, Mother To Child Transmission; NGO, nongovernmental organisation, PHRU, Perinatal HIV Research Unit.
doi:10.1371/journal.pmed.1000390.t001
Table 2. Uncorrected Kaplan-Meier estimates of programme-level mortality at 1 year for all patients starting ART, number of
patients lost to follow-up, mortality estimates for patients retained in care, predicted mortality among patients lost to follow-up,
correction factor C and corrected programme-level mortality at 1 year.
Site
Uncorrected
Estimates of
Mortality (MU),
% (95% CI)
Patients Eligible
for Calculation
of Loss to
Follow-Up
a, n
Patients
Lost to
Follow-Up,
n %( r)
Mortality among
Patients Retained
in Care (MNL), %
(95% CI)
Mortality among
Patients Lost to
Follow-Up (ML),
% (95% CI) C
Corrected
Mortality (MC),
% (95% CI)
b
Difference
between
Corrected and
Uncorrected
Mortality, %
(MC 2 MU)
A 2.7% (2.0–3.7) 1,132 32 (2.8%) 2.7% (2.0–3.7) 61.3% (29.3–88.8) 1.62 4.4% (3.1–5.7) 1.6%
B 10.8% (8.0–14.5) 369 16 (4.3%) 11.1% (8.2–14.8) 59.8% (28.3–84.8) 1.20 13.3% (10.0–17.1) 2.4%
C 6.0% (4.5–7.8) 656 28 (4.3%) 6.1% (4.6–8.0) 59.9% (28.4–84.9) 1.38 8.4% (6.3–10.7) 2.4%
D 8.9% (8.0–9.9) 2,827 160 (5.7%) 9.1% (8.2–10.2) 58.5% (27.5–84.0) 1.31 11.9% (9.9–13.7) 3.0%
E 9.1% (7.8–10.7) 1,074 70 (6.5%) 9.4% (8.0–11.0) 57.7% (27.0–83.4) 1.33 12.5% (10.1–15.0) 3.4%
F 3.8% (2.6–5.7) 632 42 (6.6%) 4.0% (2.7–5.9) 57.5% (26.9–83.3) 1.89 7.6% (5.1–10.3) 3.7%
G 11.0% (8.5–14.11) 340 28 (8.2%) 11.2% (8.7–14.4) 56.0% (25.9–82.2) 1.33 14.9% (11.4–18.8) 3.9%
H 8.2% (7.2–9.4) 2,212 258 (11.7%) 8.8% (7.7–10.0) 52.5% (23.7–79.7) 1.58 13.9% (10.4–17.3) 5.7%
I 3.0% (2.4–3.6) 3,083 518 (16.8%) 3.3% (2.7–4.0) 47.3% (20.6–75.7) 3.26 10.8% (6.2–15.6) 7.7%
J 10.6% (9.6–11.6) 3,194 904 (28.3%) 12.0% (11.0–13.2) 36.1% (13.8–66.5) 1.59 19.1% (12.5–27.4) 8.2%
K 1.3% (0.09–1.8) 1,942 558 (28.7%) 1.4% (1.0–1.9) 35.7% (13.6–66.2) 8.30 11.6% (4.9–20.0) 9.9%
Eleven antiretroviral treatment programmes in sub-Saharan Africa, ordered by increasing loss to follow-up.
aPatients with at least 9 months of potential follow-up who are at risk of being classified as lost to follow-up.
bThe corrected estimates of programme-level mortality with 95% CIs can be obtained from the web calculator available at http://www.iedea-sa.org. The 95% CI are
based on Monte Carlo simulations, taking into account uncertainty in mortality among patients lost to follow-up, uncertainty in mortality among patients remaining in
care and uncertainty in the proportion of patients lost to follow-up. See Text S1 for further details.
doi:10.1371/journal.pmed.1000390.t002
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managers to read off a correction factor for a range of plausible
mortality rates among patients lost to follow-up. This factor can
then be used to assess to what extent the mortality observed
among patients retained in care underestimates mortality at the
programme level.
We applied the nomogram method to ART programmes in sub-
Saharan Africa to estimate programme-level mortality at 1 year
after starting ART and found that the bias was modest in many
programmes, because loss to follow-up was relatively low. It is
clear from the shape of the nomogram that if the proportion of
patients lost is low (say, below 10%), the correction factor will not
be greatly affected by different assumptions for mortality among
patients lost to follow-up. In programmes with fewer than 10% of
patients lost, the mortality observed among patients retained in
care will thus generally provide a reasonable estimate, which will
underestimate programme-level mortality by only a few percent-
age points. Conversely, if a large proportion of patients are lost, as
in the case study from western Kenya (Box 1), the bias will be
substantial even if the ratio of mortality between patients lost and
not lost is relatively low, and the amount of bias will increase
steeply with higher ratios.
Mortality among patients lost to follow-up is high: Brinkhof et
al. recently reviewed studies that traced patients who became lost
to ART programmes in resource-limited settings [8]. The vital
status of about two-thirds of patients could be ascertained, and
among these many had died: in ART programmes from sub-
Saharan Africa the combined mortality from meta-analysis was
46% (95% CI 39%–54%) [8]. Patients were often lost in the first
few months of ART and died soon thereafter [8].These findings
are in accordance with previous analyses from the ART-LINC
collaboration [27] and other treatment programmes, for example
the Me ´decins Sans Frontie `res programmes in Malawi [28] and
South Africa [29], or the ART programme in Mbarara, Uganda
[25]. Of note, the percentage of patients lost to follow-up in these
programmes was associated with estimated mortality rates in the
patients lost: the estimated mortality declined from around 60% to
20% as the percentage of patients lost to the programme increased
from 5% to 50%. As discussed in detail elsewhere [8], those lost to
follow-up in programmes with high rates of loss to follow-up might
include many low-risk patients who self-transferred to another
programme, for example because of a more convenient location of
the new clinic, to avoid stigma or due to work-related reasons. The
negative association between the proportion lost and mortality
among patients lost to follow-up will attenuate the effect of a high
rate of loss to follow-up on the correction factor C.
In the absence of direct evidence, the regression analysis of
Brinkhof et al. [8] can be used to predict mortality among patients
Figure 3. Nomogram with data from 11 antiretroviral treatment programmes in sub-Saharan Africa. LTFU, lost to follow-up.
doi:10.1371/journal.pmed.1000390.g003
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sensible range of estimates of mortality, which can then be used in
analyses to adjust overall mortality. We used this approach when
applying the nomogram to the 11 ART programmes from sub-
Saharan Africa. Statistical uncertainty is, however, substantial, as
documented by the wide confidence intervals around the predicted
mortality among patients lost to follow-up (the grey area in
Figure 2), and this translated into wide confidence intervals around
the corrected estimates of programme-level mortality (see last
column of Table 2).
In addition to the statistical uncertainty, the applicability of the
results from the regression analysis must also be considered: The
studies examined loss to follow-up and mortality in the first months
after starting ART, and at present the regression model should
therefore not be used to estimate mortality among patients lost to
follow-up later on, for example in the second or third year of ART.
The different determinants of loss to follow-up, including ‘‘silent
transfer’’ to another programme (without notifying the pro-
gramme where ART was initiated), financial constraints, and
improving or deteriorating health will change with time since
starting ART, and mortality among patients lost to programmes
will change accordingly. In the present study we focused on loss to
follow-up in the first year of ART, and the use of data from the
review and meta-regression analysis was therefore appropriate. We
stress that patterns of loss to follow-up and associated mortality
may also change with calendar years, for example with increasing
CD4 cell counts at the start of ART [17].
To obtain accurate estimates of mortality among all patients
starting ART, programmes should therefore make an effort to
trace patients lost to follow-up and ascertain their vital status. The
results from these efforts should be made available to the scientific
community so that the regression model can be updated and
Figure 4. Scatterplot of uncorrected versus corrected mortality for loss to follow-up in 11 treatment programmes in sub-Saharan
Africa.
doi:10.1371/journal.pmed.1000390.g004
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of patients lost is not possible. Also note that results of studies
tracing patients lost to follow-up can be used to directly correct
estimates of mortality in the programme, for example by using
double-sampling designs or weighted Kaplan-Meier methods
[23,30]. These methods make strong assumptions, however, and
some require expert statisticians.
The nomogram method has the important advantage of
being simple and adapted to the field. Among the data used in
the nomogram the estimated or assumed mortality among
patients lost to follow-up (ML)w i l la l w a y sb ea s s o c i a t e dw i t ht h e
greatest degree of statistical uncertainty and the greatest risk of
bias. The estimates of mortality among patients remaining in
care (MNL) might, however, also be biased: some patients will
not meet criteria for loss to follow-up and their follow-up will be
censored at the last visit. Mortality rates might be higher in
these patients than in otherwise identical patients whose follow-
up time was not censored. In other words, we cannot exclude
the possibility that some degree of ‘‘informative censoring’’
might introduce some bias in our estimate of mortality among
patients retained in care. Finally, the nomogram can provide
only a sensitivity analysis without formal estimates of uncer-
tainty. We overcame this by creating a web calculator with a
user-friendly interface, which calculates 95% CI taking into
account the statistical uncertainty in the input parameters of
the nomogram.
ART programmes should strive to prevent loss to follow-up:
interventions that prevent loss to follow-up in resource-limited
settings can improve survival and are cost-effective by interna-
tional criteria [31]. For example, outreach teams that routinely
trace patients, combined with other measures, substantially reduce
loss to follow-up [18]. Financial constraints are a common reason
for not returning to the clinic [8], and mortality in programmes
that charge user fees has been shown to be higher than in those
offering free treatment [27]. Decentralization of services, task
shifting to lay care providers, longer drug refill periods for stable
patients, and provision of transport vouchers for those in need are
some of the strategies that could address this issue. Strengthening
of referral systems and regular exchange of information between
clinics, together with patient education, could increase the
recording of transfers and ensure continuity of care. Finally, when
assessing outcomes, programmes should routinely report both
mortality among patients retained in care at a given point in time
and the proportion of patients lost to follow-up at that time. A
simple nomogram can then be used to estimate mortality among
all patients who started ART.
Supporting Information
Figure S1 Nomogram for obtaining correction factors to adjust
programme-level mortality estimates, based on the observed
mortality among patients not lost to follow-up (LTFU), the
observed proportion of patients lost and an estimate of mortality
among patients lost. Horizontal axis shows ratios from 1 to 15.
Found at: doi:10.1371/journal.pmed.1000390.s001 (0.13 MB
TIF)
Figure S2 Nomogram for obtaining correction factors to adjust
programme-level mortality estimates, based on the observed
mortality among patients not lost to follow-up (LTFU), the
observed proportion of patients lost and an estimate of mortality
among patients lost. Horizontal axis shows ratios from 1 to 50.
Found at: doi:10.1371/journal.pmed.1000390.s002 (0.13 MB
TIF)
Text S1 Statistical appendix on the calculation of 95% CIs for
corrected programme-level mortality by web calculator at http://
www.iedea-sa.org.
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Background. AIDS has killed more than 25 million people
since 1981 and about 33 million people (30 million of them
in low- and middle-income countries) are now infected with
HIV, which causes AIDS. HIV destroys immune system cells,
leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, most HIV-infected people died
within 10 years of infection. Then, in 1996, highly active
antiretroviral therapy (ART) became available. For people
living in affluent, developed countries, HIV/AIDS became a
chronic condition, but for people living in low- and middle-
income countries, ART was prohibitively expensive and HIV/
AIDS remained a fatal illness. In 2003, this situation was
declared a global health emergency and governments,
international agencies, and funding bodies began to
implement plans to increase ART coverage in developing
countries. By the end of 2009, 5.25 million of the 14.6 million
people in low- and middle-income countries who needed
ART (36%) were receiving it.
Why Was This Study Done? ART program managers in
developing countries need to monitor the effectiveness of
their programs to ensure that their limited resources are
used wisely. In particular, they need accurate records of the
death (mortality) rates in their programs. However, in
resource-limited countries, many patients drop out of ART
programs. In sub-Saharan Africa, for example, only about
60% of patients are retained in ART programs 2 years after
starting therapy. In many programs, it is not known how
many of the patients lost to follow-up subsequently die, but
it is known that mortality is higher among these patients
than among those who remain in care. Thus, in programs
with high dropout rates and poor ascertainment of death in
patients lost to follow-up, estimates of the mortality of all
patients starting ART are underestimates. In this study, the
researchers develop a simple nomogram (a graphical
method for finding the value of a third variable from the
values of two other variables) to correct estimates of
program-level mortality for loss to follow-up.
What Did the Researchers Do and Find? The
researchers’ nomogram uses the percentage of patients
lost to follow and the estimated ratio of mortality between
patients lost and not lost to follow-up to provide a correction
factor that converts mortality among patients remaining in
care to mortality among all the patients in a program. The
researchers first applied their nomogram to the Academic
Model Providing Access to Healthcare (AMPATH), a large ART
program in Kenya. They used data collected by outreach
teams to estimate mortality among the 40.5% of patients lost
to follow-up at two AMPATH sites between 1 January 2005
and 31 January 2007. The uncorrected estimate of mortality
over this period was 2.8%, whereas the corrected estimate
obtained using the nomogram was 9.4%. The researchers
then applied their nomogram to 11 other African ART
programs. This time, the researchers used a statistical model
to provide estimates of mortality among patients lost to
follow-up. Mortality among patients retained in care was
1.4% to 12.0% at 1 year; loss to follow-up ranged from 2.8%
to 28.7%. The nomogram provided a correction value for
mortality among all patients in the ART program of 1.2 to 8.0,
which resulted in absolute differences between uncorrected
and corrected mortality of 1.6% to 9.8%. The largest absolute
difference was in the program with the largest percentage of
patients lost to follow-up.
What Do These Findings Mean? These findings indicate
that, in ART programs where a large percentage of patients
are lost to follow-up, program-level mortality estimates
based on the mortality among patients retained in the
program can be substantial underestimates. This bias needs
to be taken into account when comparing the effectiveness
of different programs, so the researchers recommend that all
programs routinely report mortality among patients retained
in care and the proportion of patients lost to follow-up. The
nomogram developed by the researchers can then be used
to estimate mortality among all patients who started ART
using a range of plausible mortality rates among patients
lost to follow-up. To help program managers make use of
the nomogram, the researchers provide a user-friendly web
calculator based on the nomogram on the International
epidemiologic Databases to Evaluate AIDS (IeDEA) Southern
Africa website.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000390.
N This study is further discussed in a PLoS Medicine
Perspective by Gregory Bisson
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the HIV and AIDS in Africa, and on universal access
to AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment, including the 2010
progress report (in English, French and Spanish)
N The International epidemiologic Databases to Evaluate
Aids (IeDEA) Southern Africa website provides access to a
calculator for correcting overall program-specific mortality
for loss to follow-up
Correcting Mortality on ART in Africa
PLoS Medicine | www.plosmedicine.org 11 January 2011 | Volume 8 | Issue 1 | e1000390